Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPIA | P62937 | 20/20 | 0.81 |
| ▸ | PPIB | P23284 | 12/20 | 0.73 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.73 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.73 |
| ▸ | PPIF | P30405 | 1/20 | 0.73 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.73 |
| ▸ | SLCO1B1 | Q9Y6L6 | 3/20 | 0.71 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.68 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.68 |
| ▸ | ABCC2 | Q92887 | 1/20 | 0.68 |
| ▸ | SLCO1B3 | Q9NPD5 | 1/20 | 0.68 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17523692 | 0.99 | PPIA (0.80) | PPIAPPIBCYP3A4CYP2C9PPIF | |
| SCHEMBL17523694 | 0.99 | PPIA (0.80) | PPIAPPIBCYP3A4CYP2C9PPIF | |
| SCHEMBL15183174 | 0.98 | PPIA (0.81) | PPIAPPIBCYP3A4CYP2C9PPIF | |
| SCHEMBL15183229 | 0.95 | PPIA (0.75) | PPIAPPIBCYP3A4CYP2C9PPIF | |
| SCHEMBL15183371 | 0.95 | PPIA (0.72) | PPIAPPIBCYP3A4CYP2C9PPIF | |
| SCHEMBL21983202 | 0.95 | PPIA (0.79) | PPIAPPIBCYP3A4CYP2C9PPIF | |
| SCHEMBL20076345 | 0.95 | PPIA (0.76) | PPIAPPIBCYP3A4CYP2C9PPIF | |
| SCHEMBL17523733 | 0.95 | PPIA (0.72) | PPIAPPIBCYP3A4CYP2C9PPIF | |
| SCHEMBL15183086 | 0.94 | PPIA (0.81) | PPIAPPIBCYP3A4CYP2C9PPIF | |
| SCHEMBL19860365 | 0.94 | PPIA (0.82) | PPIAPPIBCYP3A4CYP2C9PPIF |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10647747-B2 | Cyclosporin derivatives and uses thereof | S&T GLOBAL INC. (US) | 2020-05-12 | — | — | US | disclosed |
| US-20180105558-A1 | NOVEL CYCLOSPORIN DERIVATIVES AND USES THEREOF | S&T GLOBAL INC. | 2018-04-19 | — | — | US | disclosed |
| US-20180105558-A1 | NOVEL CYCLOSPORIN DERIVATIVES AND USES THEREOF | S&T GLOBAL INC. | 2018-04-19 | — | — | US | disclosed |
| US-9890198-B2 | Cyclosporin derivatives and uses thereof | S&T GLOBAL INC. (US) | 2018-02-13 | — | — | US | disclosed |
| US-20160039879-A1 | NOVEL CYCLOSPORIN DERIVATIVES AND USES THEREOF | S&T GLOBAL INC. (US) | 2016-02-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10647747-B2 | Cyclosporin derivatives and uses thereof | FKBP5, FKBP1B, MALT1 | PPIA 403/4885PPIB 35/4885CYP3A4 714/4885 |
| US-20160039879-A1 | NOVEL CYCLOSPORIN DERIVATIVES AND USES THEREOF | FKBP1B, MALT1, FKBP5 | PPIA 435/4885PPIB 39/4885CYP3A4 1071/4885 |
| US-20180105558-A1 | NOVEL CYCLOSPORIN DERIVATIVES AND USES THEREOF | FKBP1B, MALT1, FKBP5 | PPIA 435/4885PPIB 39/4885CYP3A4 1071/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.